Novartis Projects Profit Growth Despite Rising Competition for Its Top Drug

Swiss pharmaceutical giant Novartis has recently announced promising financial forecasts, projecting an increase in profits even amid the looming threat of competition from generic versions of their leading drug. This positive outlook comes as the company navigates a challenging landscape where biosimilars—biologically similar drugs—are beginning to emerge in the market.

Continue reading